Business Wire

Truffle Capital Reports Outstanding 2020 Stock Market Performance for Its Listed BioMedTech Portfolio Companies


Truffle Capital:

1. Three leading BioMedTech companies, Founded or Co-Founded and Supported by Truffle Capital since Their Inception, Generate Outstanding Performance in 2020

As of today, Abivax (EPA: ABVX), Carbios (EPA: ALCRB) and Carmat (EPA: ALCAR), are collectively capitalizing €1.3 billion (497, 443 and 379 M€ respectively) and ranking among the best 2020 stock performers listed on Euronext Paris (including Carbios at the 1st position; among the companies capitalizing between €200 million and 2 billion; see table below). These three companies are all developing radical innovations aiming at revolutionizing the medical sector or the protection of the environment.

Here are the latest companies’ breaking news for these three companies:

  • November 19, 2020: Carbios, founded by Truffle Capital in 2011 develops industrial bioprocesses for the circular economy of plastics, Carbios made its first 100% recycled plastic bottle from textiles. Based in French region of Auvergne, Carbios published a major scientific article in Nature, was able to attract renowned corporate partners (L’Oréal, Michelin, Nestlé Waters, Novozymes, PepsiCo, Suntory Beverage & Food Europe), and is now at the industrial pilot stage.
    Link: News/Carbios/First Plastic Bottle from Recycled Textile
    Link: News/Carbios/Nature Cover Page
  • December 22, 2020: Abivax, founded by Truffle Capital in 2013, is developing innovative drugs to treat patients with inflammatory diseases, viral diseases and cancers. Abivax ABX464 drug candidate was declared a National Covid-19 Research Priority by the French government for its large international clinical trial, miR-AGE, launched last May with ABX464. This BioTech company already secured €84 million in funding over the year.
    Link: News/Abivax/National Covid-19 Research Priority
  • December 23, 2020: Carmat, co-founded by Truffle Capital, Airbus and Pr Carpentier in 2008, designer and developer of the world's most advanced total artificial heart conceived to provide a therapeutic alternative for patients suffering from end-stage biventricular heart failure, obtained market approval in Europe (CE marking).
    Link: News/Carmat/CE Marking

For detailed information regarding these companies, including risk factors, please refer to their respective websites (Carbios:; Abivax: and Carmat:

These companies and their achievements are Truffle Capital's signature as an entrepreneur-investor company: sourcing radical innovations in biotechnology and medical devices from around the world to build leading companies in France and support them towards advanced development stages.

Philippe Pouletty, M.D. co-founder and CEO of Truffle Capital, mentions: “We are proud of these three French companies that would not have existed without Truffle. Contributing to saving lives or protecting our planet, thanks to exceptional scientific research and technologies and to international management teams, fosters the emergence of future World leaders in France, while generating a very good return on investment for Truffle Capital’s funds. We intend to amplify our efforts with our new BioMedTech and Medeor funds, to benefit patients around the world and our investors.”

2020 Stock Performance Ranking of Euronext Paris listed BioMedTech Companies, with a Market Capitalization between 200 million and 2 billion euros on 01/01/2020



2020 Stock Performance (%)

Market Capitalization
(M€, as of 22/01/2021)






AB Sciences












Gensight Biologics
















Innate Pharma




DBV Technologies




2020 Performance

CAC 40


Next Biotech


Sources: Price per share variation (%) from 12/31/2019 to 12/31/2020; market capitalization on 01/22/2021. Companies in the diagnostics sector or with market capitalizations less than 200 million euros or over 2 billion euros as of January 1, 2020 were excluded. This ranking was established based on Euronext data.

2. New BioMedTech Companies created by Truffle Capital in Major Healthcare Sectors

Truffle continues to create and support future BioMedTech leaders aiming to treat life threatening diseases. Truffle Early-Stage BioMedTech Funds, which closed at the end of 2019, have already enabled the financing of 8 BioMedTech companies built on promising radical innovations.

  • Affluent Medical (Aix en Provence) is developing four minimally invasive medical devices to treat cardiac, vascular and urologic diseases, which are already at an advanced clinical development stage;
  • Artedrone (Paris) is aiming to design revolutionary autonomous microrobots allowing interventional radiologists to treat or prevent cerebrovascular accidents without using catheters;
  • Bariatek (Paris) is developing a minimally invasive medical device to treat obesity;
  • Caranx Medical (Nice) is developing autonomous surgical robots, for vascular and abdominal surgery;
  • Diaccurate (Paris) is developing novel anti-cancer and anti-viral drugs based on breakthrough immuno-oncology mechanisms;
  • HoliStick Medical (Paris) is developing a medical device to close pathological holes between the right and left heart (PFO) in order to prevent strokes;
  • PKMed (Lyon), is developing biocompatible 3D implants to enable local drug delivery or to promote the genesis of functional tissues and organs following cell therapy;
  • Skinosive (Marseille) is developing bioadhesive technologies to increase the effectiveness and safety of UV filters and other dermato-cosmetic compounds.

3. MEDEOR, Truffle New Late-Stage BioMedTech Fund, expects a first closing before summer

Truffle new MEDEOR Fund aims to complement Truffle's BioMedTech financing tools for BioMedTech companies, from inception to commercial stages. It has a clear industrial objective: invest at least €600 million in future BioMedTech world leaders developing advanced-stage medical devices (pre-commercial or commercial stage, for 70%) or innovative drugs (phase II & III clinical studies, for 30%). MEDEOR will always be lead investor and major proactive shareholder and board member, to build in France technological leaders that will revolutionize surgery and medicine. French institutional investors and French government granted MEDEOR the “Tibi” label, a French government initiative to encourage LP’s to invest in the best funds.

Thanks to MEDEOR, Truffle Capital intends to continue to lead French BioTech and MedTech companies towards commercial and international medical success.

4. Truffle : a High Performance business model launched twenty years ago

Founded in 2001, Truffle Capital is an independent European Venture Capital firm focused on radical innovations in Life Sciences (MedTech and BioTech) and breakthrough technologies in the IT sector (FinTech and InsurTech). Truffle Capital's mission is to support the founding and development of young innovative companies capable of becoming tomorrow’s leaders. Chaired by Patrick Kron and managed by Dr. Philippe Pouletty and Bernard-Louis Roques, Co-Founders and Chief Executive Officers, Truffle Capital has raised more than €1.1 billion since its creation and has supported several dozens of companies in the life sciences and digital technology sectors. In 2019, Truffle Capital announced the raising of nearly €400 million for its early-stage institutional funds, including €250 million dedicated to BioMedTech.

2020 was marked by the launch of new innovative projects in its two areas of expertise (BioMedTech and FinTech/InsurTech) and by very significant advances in the field of Biotechnology and Medical Devices.


For more information: — Twitter: @trufflecapital

Contact information

Truffle Capital Investor Relations: Maud Lazare –

Media Relations Agency – DGM Conseil
Quentin Hua – (+ 33 6 28 63 27 29)
Thomas de Climens – (+33 6 14 50 15 84)
Hugues Schmitt –
Olivier Labesse –

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Colicity Inc. Announces Closing of $345 Million Initial Public Offering26.2.2021 23:00:00 CETPress release

Colicity Inc. (the “Company”) announced the closing today of its initial public offering of 34,500,000 units, including the underwriters’ exercise of their full over-allotment option for 4,500,000 units, at a price of $10.00 per unit. The units are listed on the NASDAQ Stock Market (NASDAQ) and began trading under the ticker symbol “COLIU” on February 24, 2021. Each unit consists of one Class A share and one-fifth of one redeemable warrant, with each whole warrant exercisable to purchase one Class A share at a price of $11.50 per share. Only whole warrants will be exercisable. Once the securities comprising the units begin separate trading, the Class A shares and warrants are expected to be listed on the NASDAQ under the symbols “COLI” and “COLIW,” respectively. Colicity Inc. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company int

C3 AI and Baker Hughes to Provide Enterprise AI Solutions to Accelerate PETRONAS Digital Transformation Program26.2.2021 15:00:00 CETPress release

C3 AI (NYSE: AI) and Baker Hughes today announced an artificial intelligence (AI) collaboration with PETRONAS, a global energy and solutions company from Malaysia, to apply (BHC3) technology across PETRONAS’s strategic digital transformation programs. As the custodian of Malaysia's national oil and gas resources, PETRONAS runs an extensive digital transformation program across energy operations to extract value from data. The adoption of AI as part of its overall program for improved oil and gas productivity, asset integrity, and safety supports PETRONAS’s commitment to provide clean, efficient energy solutions by harnessing the power of technology. PETRONAS will work with energy technology, data science, and AI experts at Baker Hughes and C3 AI to collaborate on projects focused on improved reliability of energy assets in critical operations. Utilizing Microsoft Azure, PETRONAS will deploy the BHC3™ Reliability application to further improve maintenance programs for g

Avania in Position for Next Stage of Growth26.2.2021 14:00:00 CETPress release

Avania, a leading global full-service contract research organization (CRO) focused on medical technology (MedTech) development, today announced that it has successfully refinanced its existing banking facilities with Crescent Capital Group. “This new banking facility allows us to accelerate our next phase of organic and acquisitive growth over the next few years,” said Edo van Houten, CFO of Avania. “This transaction is also a reflection of the progress we have made in our brand strategy and position in the market, and it demonstrates the confidence of the financial community in our operational and strategic plan.” Avania has navigated confidently through the COVID-19 pandemic, posting a strong year of growth in 2020 despite the pandemic. The company will continue its growth trajectory as a global MedTech-focused CRO, supporting products from concept through post-market support. MedTech is all Avania does, navigating innovative medical technologies to market effectively and efficiently

Ipsen Receives Positive CHMP Opinion Recommending Cabometyx ® in Combination With Opdivo ® as First-line Treatment for Patients Living With Advanced Renal Cell Carcinoma26.2.2021 12:37:00 CETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) for the first-line treatment of advanced renal cell carcinoma (aRCC). The European Commission, which has the authority to approve medicines for the European Union (E.U.), will now review the CHMP recommendation and a final decision on the application in the E.U. is expected in the coming months. “Advanced renal cell carcinoma is a disease that significantly impacts the lives of people around the world. We’re proud to be able to share that the CHMP has confirmed a positive recommendation for Cabometyx® in combination with Opdivo®, bringing this impactful new treatment option one step closer for patients,” said Howard Mayer, Executive Vice President and Head of Research and Development, Ipsen. “At Ipsen, w

Hiro Capital Leads $15 Million of Games VC Investment Into Snowprint Studios, Double Loop Games and Happy Volcano Games26.2.2021 09:55:00 CETPress release

Three international video game studios are the latest investments for Hiro Capital, the entrepreneur-led Venture Capital fund focused on backing innovators in Video Games, the Metaverse, Esports and Digital Fitness. The three mobile and cross-platform studios – Snowprint in Stockholm/Berlin, Double Loop Games in San Francisco and Happy Volcano in Belgium – will use Hiro’s investment to expand their development pipelines and accelerate global growth. They join UK and US Games studios Flavourworks, Polyarc and Lightfox in the Hiro Capital portfolio, alongside pioneers in the gamification of Games Streaming and Digital Fitness, Edgegap,FitXR and Nurvv. Ian Livingstone, co-founding partner at Hiro Capital, said, "We are excited to begin 2021 by announcing Hiro's investment in three amazing games studios, Snowprint, Double Loop and Happy Volcano. Each studio has demonstrated innovation and expertise in developing fun to play games which resonate with today’s audiences. I’m especially

Inspur Information Releases 2020 Global Computing Index Report26.2.2021 09:07:00 CETPress release

Inspur Information, a leading IT infrastructure solutions provider, has sponsored an International Data Corporation (IDC) white paper on the 2020 Global Computing Index (henceforth referred to as The Report). As the world’s first index report on computing, The Report unveils the relationship between computing power and economic development and serves as a reference for the outlook of the global digital economy. Global digital transformation has entered a phase marked by exponential growth in innovation, with the size of the digital economy projected to continue on an upward trend. As a key factor that underlies digital technology development, computing is now defining the productivity of the digital economy era. According to The Report, economic growth directly correlates with the development of computing—one point of growth in the computing index translates to a 3.3‰ rise in the size of the digital economy and a 1.8‰ growth in GDP. Specifically, AI computing market share is projected

Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)26.2.2021 09:00:00 CETPress release

Incyte (Nasdaq:INCY) today announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group Vice President, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent U.S. Food & Drug Administration acceptance of our Biologics License Application for Priority Review – brings us